Tag: targeted therapy
-
Bezuclastinib Peaks in GIST: Positive PEAK Phase 3 Results for KIT Exon 17/18 Mutants
New Phase 3 data positions Bezuclastinib as a potential new standard for KIT Exon 17/18 mutant GIST In a pivotal development for patients with advanced gastrointestinal stromal tumors (GISTs), Bezuclastinib demonstrated positive outcomes in the PEAK Phase 3 study focusing on KIT exon 17/18 mutant disease. GISTs are driven by complex mutations in the KIT…
-
Bezuclastinib Achieves Positive PEAK Phase 3 Results in Advanced GIST: A Potential New Standard for KIT Exon 17/18 Mutant Disease
Bezuclastinib Makes a Major Leap in KIT Exon 17/18 Mutant GIST Recent PEAK Phase 3 results are positioning Bezuclinib as a potentially practice-changing therapy for patients with advanced gastrointestinal stromal tumors (GIST) driven by KIT Exon 17/18 mutations. These mutations have long been associated with primary resistance to first-line therapies and later-line inhibitors, making the…
-
Bezuclastinib PEAK Phase 3: A Potential New Standard for KIT Exon 17/18 GIST
Bezuclastinib Hits Positive PEAK Phase 3 Results in Advanced GIST Gastrointestinal stromal tumors (GIST) have long been driven by KIT mutations, with targeted therapies reshaping patient outcomes over the past two decades. The emergence of resistance, particularly in those with KIT Exon 17 and Exon 18 mutations, has remained a persistent challenge. Bezuclastinib’s latest PEAK…
-
IFITM3-MET Interaction Drives Osimertinib Resistance in EGFR-Mutant NSCLC
Overview: A New Mechanism Behind Osimertinib Resistance in EGFR-Mutant NSCLC Osimertinib has transformed the treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Yet resistance remains a major hurdle. A recent study identifies a non-genetic mechanism: the membrane protein IFITM3 interacts with MET to activate the PI3K-AKT signaling axis, enabling tumor cells to…
-
MAEA Protein’s New Role Could Boost Chemotherapy Response
New findings reveal MAEA’s unexpected function in DNA repair and cancer therapy A University of Alberta research team has uncovered a surprising new role for the MAEA protein, historically associated with red blood cell development and linked to developmental disorders. In a study published in Science Advances, the researchers show that MAEA also helps control…
-
Blocking PDIA1 and PDIA5: A New Strategy to Weaken Prostate Tumors and Boost Drug Effectiveness
New vulnerability in prostate cancer identified: two enzymes that protect the androgen receptor A major international study has uncovered a promising vulnerability in prostate cancer cells that could improve treatment for one of the most common cancers in men. Published in the Proceedings of the National Academy of Sciences (PNAS), the research shows that two…
-
Blocking two enzymes weakens prostate tumors and boosts drug effectiveness
New vulnerability uncovered in prostate cancer: targeting PDIA1 and PDIA5 A major international study has identified a promising vulnerability in prostate cancer cells that could improve how this common male cancer is treated. Published in the Proceedings of the National Academy of Sciences (PNAS), researchers from Flinders University in Australia and the South China University…
-
Genetic Link to Osteosarcoma Found: SMARCAL1 Gene Inheritance Raises Risk in Children
Breakthrough in Pediatric Cancer Genetics A collaborative study led by researchers at Cleveland Clinic Children’s has identified an inherited genetic factor that may elevate the risk of osteosarcoma, the most common malignant bone tumor in children and young adults. Published in the Journal of Clinical Oncology, the work analyzed genetic data from thousands of cancer…
-
New Compound Shows Promise in Blocking Lung Cancer Growth
A Promising Breakthrough in Lung Cancer Treatment Researchers are reporting a promising advance in the fight against lung cancer: a novel small-molecule compound that effectively blocks the growth of cancer cells in preclinical studies. The compound targets a key signaling axis that many lung tumors rely on to proliferate and evade cell death. In laboratory…